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Context: The importance of vitamin D for bone health has long been acknowledged. Recent
evidence suggests that vitamin D can also play a role in reducing the risk of several other diseases,
including cardiovascular disease.
Objective: The aim of this study is to test the hypothesis that 25-hydroxyvitamin D (25-OH D) is an inde-
pendent cross-sectional correlate of central arterial stiffness in a normative aging study population.
Design and Settings: We conducted a cross-sectional analysis.
Subjects: We studied 1228 healthy volunteers (50% males; age, 70  12 yr) of the Baltimore
Longitudinal Study of Aging.
Main Outcome Measures:We measured carotid-femoral pulse wave velocity (PWV) and 25-OH D
levels.
Results:Wefounda significant inverse associationbetweenPWVand25-OHD levels (adjusted r2
0.27;   0.43; P  0.001). After adjusting for age, gender, ethnicity, season of blood draw,
estimated glomerular filtration rate, physical activity level, cardiovascular risk factors score (smok-
ing, visceral obesity, hypercholesterolemia, hypertension, and diabetes), calcium/vitamin D sup-
plementation, serumcalcium, andPTH levels, theassociationbetweenPWVand25-OHD levelswas
only slightly reduced and remained statistically significant (adjusted r2 0.34;0.34; P 0.04).
Conclusions: Vitamin D levels are inversely associated with increased arterial stiffness in a norma-
tive aging population, irrespective of traditional risk factor burden. Further research is needed to
understand the mechanism of this association and to test the hypothesis that vitamin D supple-
mentation can reduce arterial stiffness. (J Clin Endocrinol Metab 97: 3717–3723, 2012)
The importance of vitamin D for bone health has longbeen acknowledged. Recent evidence suggests that
vitaminDcanalsoplaya role in reducing the riskof several
other diseases, including cardiovascular disease (1, 2). Vi-
tamin D deficiency is a highly prevalent condition affect-
ing up to 50% of the U.S. population and is associated
with hypertension, insulin resistance, congestive heart
failure, and blood levels of inflammatory markers (1, 2).
Mechanisms underlying vitamin D deficiency-medi-
ated increased risk of cardiovascular disease still remain
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unclear. The evidence that endothelial cells express a vi-
tamin D receptor and possess the enzymatic system to
convert the primary circulating form of vitamin D, 25-
hydroxyvitamin D (25-OH D), to the active form, 1,25-
dihydroxyvitamin D, has provided new working hypoth-
eses into the function of this vitamin (3, 4). Vitamin D
influences endothelial and smoothmuscle cell function by
exerting antiproliferative effects on vascular smoothmus-
cle (5), mediates inflammation by regulating lymphocyte
andmonocytes/macrophage differentiation and release of
inflammatory cytokines (6), and modulates the renin-
angiotensin-aldosterone system (RAAS) (7). This in turn
might determine monocyte infiltration and cholesterol re-
tention in the vascular wall contributing to the atheroscle-
rotic process (8, 9).
The aim of this project was to investigate the relation-
ship between25-OHDplasma levels and arterial stiffness,
with the hypothesis that arterial stiffness [measured by
carotid-femoral pulse wave velocity (PWV)] is associated
with vitamin D levels independent of age. We also ex-
plored the putative role of factors that may confound this
relationship.
Subjects and Methods
Study population
The Baltimore Longitudinal Study of Aging (BLSA) is a pro-
spective study of normative aging conducted by the National
Institute on Aging, Intramural Research Program since 1958.
BLSA participants are healthy volunteers 31–97 yr of age who
undergo standardized testing across multiple body systems over
2 to 3 d at regular intervals (10). The study cohort for this cross-
sectional analysis included all participants with 25-OH D levels
and PWV data obtained during their regularly scheduled BLSA
study visit.
Anthropometrics, smoking status assessment, and
physical activity level
Height (in meters) and weight (in kilograms) were measured
for all participants. Body mass index (BMI) was calculated as
bodyweight (inkilograms)dividedbyheight (inmeters) squared.
Obesity was defined as a BMI of 30 kg/m2 and above. Visceral
obesity was defined as waist circumference greater than 102 cm
in men and 88 cm in women. Systolic and diastolic blood pres-
sure, mean arterial pressure, and heart rate determinations were
performed at the time of PWV analysis with an oscillometric
device (Dash 4000 Monitor; General Electric, Milwaukee, WI),
after a 5-min quiet resting period. Hypertension, hypercholes-
terolemia, and diabetes mellitus were defined according to the
Seventh Report of the Joint National Committee on the Preven-
tion, Detection, Evaluation and Treatment of High Blood Pres-
sure; Adult Treatment Panel III; and American Diabetes Asso-
ciation criteria, respectively (11–13). Smoking status was
ascertained by a questionnaire that classified each subject as an
ever or never smoker. Medication use (antihypertensives and
hypoglycemic agents), and calcium and/or vitamin D supple-
mentation were also verified at the time of the BLSA visit. Par-
ticipants were classified with respect to their levels of weekly
physical activity and exercise program [metabolic equivalents
(MET) per week] using validated standard questionnaires (14).
Alcohol intake data were ascertained by a questionnaire. We
defined a standard serving of alcohol as 13.7 g of ethanol and
categorized average alcohol consumption as none or less than
one, one to less than three, or at least three servingsperweek (15).
Laboratory testing
Blood samples were drawn at rest from the antecubital vein
after anovernight fast between0700and0800h. Serumalbumin
was measured with a commercial enzymatic test (Roche Diag-
nostics GmbH, Mannheim, Germany). Automated chemical
analysis was used for analysis of calcium and creatinine. Cor-
rected calcium (Cac)was computed asCac (4.0 g/dl (plasma
albumin)) 0.8 (serum calcium) as previously reported (16).
Estimated glomerular filtration rate (eGFR) was computed ac-
cording the Modification of Diet in Renal Disease Study
(MDRD) equation (17). Concentrations of plasma triglycerides
and total cholesterol were determined by enzymatic method
(ABA-200 ATC Biochromatic Analyzer; Abbott Laboratories,
Irving, TX). The concentration of high-density lipoprotein cho-
lesterol was determined by a dextran sulfate-magnesium precip-
itation procedure. Low-density lipoprotein cholesterol concen-
trations were estimated by using the Friedewald formula. The
fasting plasma glucose concentration was measured by the glu-
cose oxidase method (Beckman Instruments, Inc., Fullerton,
CA). Serum intact PTH (iPTH) was determined using a chemi-
luminometric immunoassay (ADVIA Centaur iPTH; Siemens
Medical Solutions Diagnostics, New York, NY), with an inter-
assay variation coefficient of approximately 8%. Serum 25-OH
D levels were assayed in duplicate and measured by liquid chro-
matography-mass spectrometry at Mayo Clinic laboratories
(Rochester, MN) within 1 wk from data collection. Serum was
obtained within 3 h from blood collection and stored at80 C.
Serum was collected and maintained in iced water until pro-
cessed. Lower detection limit was 4 ng/ml, and the interassay
coefficient of variation was 10%.
Arterial stiffness testing
Evaluation was performed in the supine position in a dark,
quiet room. After simultaneous acquisition of pressure wave-
forms in the right common carotid artery and right femoral ar-
tery, pulse transit times between these two sites were automat-
ically measured by the Complior SP device (Artech Medical,
Paris, France), as previously described and validated (18). The
distance traveled by the pulse wave was measured to the nearest
centimeter with an external tape measure over the body surface.
This distance wasmeasured by subtracting the distance between
themanubriumand the carotid sampling site from the sumof the
distances between the manubrium and the umbilicus and the
umbilicus and the femoral sampling site. PWVwas calculated by
dividing the distance traveled by the pulse wave by the pulse
transit time. Measurements of PWVwere made in triplicate and
averaged for the analyses.
Statistical analysis
Study variables are described as the mean  SD (unless oth-
erwise specified) for continuous variables or as counts or pro-
portions for categorical variables. Age, BMI, 25-OH D levels,
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lipid profile, and PWV values were treated as continuous vari-
ables. Diagnosed hypertension, hypercholesterolemia, diabetes
mellitus, smoking, gender, medication use (antihypertensive
drugs or glucose-lowering agents), and vitamin D/calcium sup-
plementation were categorical variables. Continuous variables
were tested for normality with the Kolmogorov-Smirnov crite-
rion. Skewedvariableswere log-transformedand testedagain for
normality before any parametric analysis. Univariate correla-
tions between 25-OH D concentrations and measured parame-
ters were performed with Pearson’s correlation. Differences in
age-adjustedmeans of PWV across 25-OHD tertiles were tested
by general linearmodels.Multiple linear regression analysis was
used to test the association between PWV and 25-OH D levels.
Models adjusted for potential confounding factors based upon a
review of the relevant literature, including age, gender, race, sea-
son of blood draw, eGFR, physical activity level, cardiovascular
risk score (visceral obesity, smoking, hypercholesterolemia, hy-
pertension, and diabetes), calcium and vitamin D supplements,
serum calcium, and iPTH levels. Multicollinearity among the
covariates was tested using the variance inflation factor. Statis-
tical significance was based on two-tailed tests, and P values
0.05 were considered significant. All analyses were performed
using SAS (version 9.1; SAS Institute, Inc., Cary, NC) with sig-
nificance set at P  0.05.
Results
Baseline characteristics of the 1288 subjects are shown in
Table 1. Mean 25-OH D level was 34 ng/ml (range, 7 to
89 ng/ml) and mean PWV was 8.6  2.0 m/sec.
Relationship between vitamin D levels and subject
characteristics
Serum 25-OHDwas significantly lower in men and in
both African-Americans men and women, and in subjects
with the highest cardiovascular risk scores (Table 2). Af-
rican-Americans were more likely to have hypertension
(64 vs. 46%; P  0.001) and obesity (33 vs. 22%; P 
0.001) compared with Caucasians, whereas there was no
difference for diabetes and hypercholesterolemia. Thirty-
seven percent of participants had 25-OH D levels below
30 ng/ml, and 10% of participants had 25-OH D levels
below 20 ng/ml. Across participant subgroups with
25-OHD below 20 ng/ml, between 20 and 30 ng/ml, and
above 30 ng/ml, there was a significant difference in sys-
tolic blood pressure [systolic blood pressure 129 16,
126  16, and 124  17 mm Hg, respectively (P 
0.0001)]; in diastolic blood pressure [diastolic blood pres-
sure 69 8, 67 10, and 66 10mmHg, respectively
(P  0.003)]; in BMI [BMI  29.5  0.4, 28  0.2, and
26  0.2 kg/m2, respectively (P  0.0001)]; and in PWV
[PWV  9.0  0.2, 8.7  0.9, and 8.5  0.6 m/sec, re-
spectively (P  0.02)]. Twenty-nine percent of African-
Americans had 25-OHD levels below 30 ng/ml, and 24%
had 25-OH D levels below 20 ng/ml; whereas 25% of
Caucasians had 25-OHD levels below 30 ng/ml, and 4%
had 25-OHD levels below 20 ng/ml (P 0.0001 between
groups). Twenty-three percent of the study cohort was
obese. Among obese participants, 36%had 25-OHD lev-
els below 30 ng/ml, and 17% had 25-OH D levels below
20 ng/ml.
Participants taking regular vitamin D supplementation
had higher 25-OH D levels (40.9  12.1 vs. 35.5  11.2
ng/ml; P  0.0001) and were significantly older (73.6 
10.5 vs. 71.6  11.7 yr; P  0.02). African-Americans
were less likely to be taking vitamin D supplementation
compared with Caucasians (34 vs. 46%; P  0.0001).
Relationship between PWV and subject
characteristics
No differences in mean PWVwere observed between
Caucasian and African-American cohorts (8.8 2.0 vs.
TABLE 1. Descriptive and clinical characteristics of the
study cohort (n  1228)
Demographics
Age (yr) 70  12
Male, n (%) 648 (50)
BMI (kg/m2) 27  4
Waist circumference (cm) 91  12
Caucasian, n (%) 799 (65)
African-American, n (%) 335 (27)
Smoking, n (%) 573 (48)
Physical activity level (MET/wk) 95  66
Alcohol intake (drinks/wk)a
None or 1, n (%) 285 (28)
1 to 3, n (%) 287 (29)
 3, n (%) 419 (13)
Hypertension, n (%) 628 (50)
Hypercholesterolemia, n (%) 479 (37)
Obesity, n (%) 281 (23)
Diabetes, n (%) 273 (22)
Cardiovascular parameters
Systolic blood pressure (mm Hg) 125  17
Diastolic blood pressure (mm Hg) 66  9
Mean arterial pressure (mm Hg) 98  12
Heart rate (beats/min) 64  10
PWV (m/sec) 8.6  2.0
Medications
Antihypertensive drugs, n (%) 562/628 (89.5)
Hypoglycemic agents, n (%) 114 (14.6)
Calcium and Vitamin D supplements,
n (%) 549 (42.6)
Hormone replacement therapy,
n (%) women	 70 (5.4)
Laboratory
Fasting glucose (mg/dl) 90  17
Creatinine (mg/dl) 1.0  0.3
Albumin (g/dl) 4.2  0.3
eGFR (ml/min/1.73 m2) 77  18
Cac (mg/dl) 9.2  0.4
Total cholesterol (mg/dl) 189  38
LDL-cholesterol (mg/dl) 110  33
HDL-cholesterol (mg/dl) 59  16
Triglycerides (mg/dl) 101  56
PTH (pg/ml) 38  18
25-OH D (ng/ml) 34  12
Data are expressed as mean  SD or proportions. HDL, High-density
lipoprotein; LDL, low-density lipoprotein.
a Missing  297.
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8.7  2.1 m/sec, respectively; P  0.27). PWV was sig-
nificantly higher among subjects with hypertension
(9.1 1.9 vs. 8.0 2.1 m/sec, respectively; P 0.001)
and diabetes (9.3 2.0 vs. 8.4 2.1m/sec, respectively;
P  0.001); whereas no differences were observed in
mean PWV according to obesity (8.7 1.9 vs. 8.6 2.1
m/sec, respectively; P 0.30) and smoking (8.7 1.9 vs.
8.5  2.1 m/sec, respectively; P  0.19). Highest PWV
tertiles (11.0  1.5 m/sec) were associated with lower
physical activity levels (93.4 MET/wk) (P  0.0001);
whereas lower PWV tertiles (mean PWV  6.6  0.6
m/sec) were associated with the highest physical activity
level tertiles (99.3 MET/wk) (P  0.0001).
Relationship between vitamin D levels and arterial
stiffness
After adjusting for age, we found a significant inverse
correlation between PWV and 25-OH D levels ( 
0.43;P0.001). Subjects in the lowest 25-OHDtertiles
(20 ng/ml) showed the highest PWV (8.8 m/sec), com-
pared with second to third tertiles (8.6 m/sec, 8.5 m/sec,
respectively; p for trend  0.04).
To verify whether the association between 25-OH D
and PWV was not attributable to confounding variables
known to be associated with PWV and 25-OH D levels
were added as covariates in the age- and sex-adjusted lin-
earmodel relatingPWVto25-OHDlevels (Table 3).After
adjusting for age, gender, race, and season of blood draw,
the association between PWV and 25-OH D levels re-
mained highly statistically significant (Table 3, model 1).
The association between PWV and 25-OH D levels re-
mained unchanged after eGFR was added to the model
(Table 3, model 2). Similarly, this association remained
significant after adjusting for physical activity level and a
cardiovascular risk score (visceral obesity, smoking, hy-
percholesterolemia, hypertension, and diabetes; Table 3,
model 3). Finally, the association between PWVand25-OH
D levels still remained significant after adjusting for calcium
and vitaminD supplements, serumcalcium (Cac), and iPTH
levels (Table 3, model 4). A 25-OH D by-sex and -race in-
teraction termwas also included in the fully adjustedmodel.
The interaction term was not statistically significant, sug-
gesting that the nature of association between PWV and
25-OHDlevels is substantially similar among the sexgroup.
Separate analysis in the nonsmoker cohort showed that after
adjusting for age, gender, race, season of blood draw, phys-
ical activity level, calciumandvitaminDsupplements, serum
calcium, and iPTH levels, the association between PWVand
25-OHD levels remained significant [0.46; Stb (stan-
dardized beta)0.09; P 0.04].
Discussion
In the present study, we found an inverse association be-
tween arterial stiffness and 25-OH D levels, independent
TABLE 2. Relationship between vitamin D status and
subject characteristics
ng/ml P value
Gender
Men 33.0  10.8 0.0001
Women 35.6  12.9
Race
Caucasian 36.0  10.8 0.0001
African-American 30.2  13.4
Vitamin D supplement
Yes 40.9  12.1 0.0001
No 35.3  11.2
Cardiovascular risk scoreb
0–1 34.4  0.5 0.05a
2–3 34.6  0.4
4–5 31.5  0.2
a P for trend.
b Cardiovascular risk score  visceral obesity (yes/no), smoking (yes/
no), hypertension (yes/no), hypercholesterolemia (yes/no), and diabetes
(yes/no).
TABLE 3. Hierarchical multivariate models examining the relationship between PWV and 25-OH D levels
Covariates
Model 1 Model 2 Model 3 Model 4
Std  P Std  P Std  P B Std  P
Age (yr) 0.50 0.0001 0.52 0.0001 0.47 0.0001 0.07 0.47 0.0001
Gender (men) 0.14 0.0001 0.14 0.0001 0.16 0.0001 0.66 0.16 0.0001
Race (Caucasian) 0.02 0.24 0.03 0.18 0.03 0.17 0.07 0.05 0.07
Season of blood draw (autumn/winter) 0.12 0.0001 0.12 0.0001 0.11 0.0001 0.61 0.14 0.0001
eGFR (ml/min/1.73 m2) 0.05 0.02 0.05 0.03 0.008 0.07 0.02
Physical activity level (MET/wk) 0.05 0.07 0.001 0.05 0.11
Cardiovascular risk scorea 0.07 0.003 0.15 0.09 0.005
Calcium/vitamin D supplements 0.14 0.03 0.28
Serum Cac (mg/dl) 0.04 0.06 0.03
iPTH (pg/ml) 0.03 0.008 0.78
25-OH D (ng/dl) 0.07 0.005 0.06 0.006 0.05 0.03 0.34 0.07 0.04
For each model, standardized -coefficient (Std B) and P values are given. For model 4, unstandardized -coefficient (B), Std B, and P values are
given. In parentheses, reference values or units are given where appropriate.
a Cardiovascular risk score  visceral obesity (yes/no), smoking (yes/no), hypertension (yes/no), hypercholesterolemia (yes/no), and diabetes
(yes/no).
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of age and several confounders. We studied a large mul-
tiethnic population over a wide age range and with a rel-
atively low risk factors burden, and we used state-of-the
art methods to assess arterial stiffness. These findings are
in line with the well-established associations between vi-
tamin D deficiency and a broad range of cardiovascular
disorders and risk factors (1), providing a possible expla-
nation of how lower vitamin D levels, by precipitating
vascular stiffening, might predispose individuals to a
higher risk for development of cardiovascular disease and
adverse events.
Arterial stiffness increases with advancing age (19) and
is a powerful predictor of mortality and morbidity (20,
21), hypertension (22), and decline in cognitive function
(23). Accumulating evidence suggests that cardiovascular
disease is associated with vitamin D deficiency. Various
epidemiological studies have reported reduced 25-OH D
concentrations in patients with previous and prevalent
cardiovascular or cerebrovascular diseases (24, 25). Pop-
ulation-based studies have partially, but not consistently,
documented that poor vitamin D status is associated with
an increased risk of cardiovascular events and cardiovas-
cular mortality (26–28). Meta-analyses performed so far
on this topic support the finding that low 25-OH D con-
centrations are associated with incident cardiovascular
disease (29). In this context, Grandi et al. (25) found that
the risk of cardiovascularmortalitywas increased by 83%
(hazard ratio, 1.83; 95% confidence interval, 1.19–2.80)
in individuals with low 25-OH D levels. Data from ran-
domized controlled trials are sparse andhavepartially, but
not consistently, shown some beneficial effects of vitamin
D supplementation on cardiovascular risk factors (30,
31). Of note, Al Mheid et al. (32) recently reported that
vitamin D insufficiency is associated with increased arte-
rial stiffness and endothelial dysfunction in healthy sub-
jects. Interestingly, these authors found that in 42 subjects
with vitamin D insufficiency, normalization of 25-OH D
at 6 months was associated with increases in reactive hy-
peremia index and subendocardial viability ratio, and a
decrease in mean arterial pressure (32). In a random sam-
ple of 560 subjects selected from the general population,
Mayer et al. (33) reported a negative trend in PWVamong
25-OH D quartiles. These authors found that subjects in
the lowest 25-OH D quartile (20 ng/ml) showed the
highest aortic PWV(9.04m/sec), comparedwith second to
fourth quartiles (8.07, 7.93, and 7.70 m/sec, respectively;
P for trend 0.0001) (33). The association between
25-OHDand PWV remained significant after adjustment
for age, gender, andother potential confounders including
hypertension, obesity, lipid profile, kidney function, drug
treatment (statin, antihypertensives), and history of car-
diovascular disease (33). More recently, Lee et al. (34)
reported that low25-OHDlevels independentlypredicted
PWV (P 0.001) in individuals with type 2 diabetes (n
305) after adjustment for other risk factors such as age,
smoking, hypertension, C-reactive protein, diabetes du-
ration, hypertension duration, glycated hemoglobin, and
BMI.
Evidence is accumulating that vitamin D may also
exert various direct effects on the cardiovascular system
(1). Heart and blood vessels are target tissues for vita-
min D and express both vitamin D receptor (VDR) and
1-hydroxylase. VDR-knockout and 1-hydroxylase-
knockout mice develop heart failure despite normalized
calcium levels (35). Increased activation of the RAAS
seems to be the mediating pathway because RAAS
blockade with, for example, the angiotensin-converting
enzyme inhibitor captopril reverses cardiac abnormali-
ties in these mouse models (35, 36). The crucial role of
vitamin D for myocardial health is further supported by
increased VDR expression in myocardial hypertrophy
(37). VDR expression increased in cardiac myocytes and
fibroblasts after treatment with the prohypertrophic va-
soactive peptide endothelin. Experimental studies docu-
mented antihypertrophic and antiproliferative actions of
vitaminDmetabolites,whichdown-regulate several genes
involved in the development of myocardial hypertrophy.
VDR activation modulates cardiac calcium flux and
thereby induces an accelerated relaxation of cardiomyo-
cytes, which may improve diastolic function of the heart.
Vitamin D-mediated regulation of cardiac extracellular
matrix turnover may also be important to maintain car-
diac health (38). Vitamin D may also protect against ath-
erosclerosis, vascular calcification, and endothelial dys-
function. Antiatherosclerotic vitamin D effects may
include inhibition of macrophage cholesterol uptake and
foam cell formation, down-regulation of vascular smooth
muscle cell proliferation and migration, and suppression
of inflammation-triggered endothelial activation and ex-
pression of endothelial adhesion molecules (8, 27, 39).
Vitamin D effects may also protect against endothelial
dysfunction, for example, by antioxidative actions and by
inhibiting lipid peroxidation (27). Finally, vitamin Dmay
reduce vascular calcification, for example, by inhibiting
bone morphogenic proteins, but data on this topic are
somewhat controversial (27).Conversely, vitaminDover-
load is used as a model of vascular stiffening (39). There-
fore, poor vitamin D status as well as vitamin D intoxi-
cationmay contribute to vascular calcification (8, 27, 40).
Observational and interventional studies showed incon-
sistent results regarding the association of vitamin Dwith
subclinical atherosclerosismarkers such as carotid intima-
media thickness (27, 41). Several, but not all, interven-
tional studies showed that vitaminD supplementation im-
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proves endothelial function (8, 36, 42). Therefore, large
trials assessing the effect of vitaminD supplementation on
vascular structure and endothelial function in individuals
with vitamin D deficiency are encouraged.
Study limitations
The cross-sectional, observational design of the present
study precludes definitive conclusions regarding the
causal relationship between arterial stiffness and vitamin
D levels. It should be also highlighted that the magnitude
of contribution of low 25-OHD status to arterial stiffness
might be variable and modest. The BLSA population is a
series of volunteers who are healthy at the time of enroll-
ment and tend to be highly educated and to have a high
socio-economic status. Thus, not surprisingly, the preva-
lence of vitamin D deficiency in the BLSA is lower than in
other published studies. A limitation of this study is that
information on important determinants of serum 25-OH
D concentration, such as sun exposure and vitamin D in-
take from food sources,were not collected. In addition,we
did not explore the putative mediating effect of alcohol
consumption.Moderate, regular alcohol consumption by
apparently healthy people is associated with lower car-
diovascular morbidity and mortality than in abstainers
(15). Mechanisms supporting this include beneficial reg-
ulation of lipids and fibrinolysis, decreased platelet aggre-
gation and coagulation factors, beneficial effects on en-
dothelial function, and inflammation and insulin
resistance. Of note, 43% of participants reported more
than three servings per week. However, because such in-
formation is missing for about 25% of the study popula-
tion (297 participants), alcohol consumption data were
not included in the regression model as covariate. Finally,
in this study we did not explore the putative mediating
effect of inflammatory status. Despite the aforementioned
limitations, this study has several unique strengths. First,
this study measured carotid-femoral PWV, which is the
“gold standard” for the noninvasive assessment of arterial
stiffness. Second, this study was performed in the context
of a normative aging study that included both sexes with
careful assessment of several potential confounders of the
arterial stiffness/vitamin D status relationship.
Conclusions
Vitamin D levels are associated with increased arte-
rial stiffness in a normative aging population, irrespec-
tive of traditional risk factors burden. Further research
is needed to further clarify the mechanisms by which
vitamin D affects arterial stiffness and to test the hy-
pothesis that vitamin D supplementation may prevent
cardiovascular disease.
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